Comparison of Tamsulosin and Silodosin in the Management of Acute Urinary Retention Secondary to Benign Prostatic Enlargement

Gufran  Ahmed; Badar  Murtaza; Umair  Ahmed; Ammar Yasir  Khan; Muhammad Talha  Akhtar; Muhammad Farooq  Shahid

doi:10.51253/pafmj.v75iSUPPL-7.12723

Authors

Gufran Ahmed Department of Urology, Armed Forces Institute of Urology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Badar Murtaza Department of Urology, Armed Forces Institute of Urology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Umair Ahmed Department of Urology, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Ammar Yasir Khan Department of Urology, Armed Forces Institute of Urology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Muhammad Talha Akhtar Department of Urology, Armed Forces Institute of Urology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Muhammad Farooq Shahid Department of Urology, Armed Forces Institute of Urology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75iSUPPL-7.12723

Keywords:

Acute Urinary Retention, Benign Prostatic Enlargement, Trial Without Catheter

Abstract

Objective: To compare the efficacy of tamsulosin and silodosin in patients suffering from acute urinary retention.

Study Design: Quasi experimental study.

Place and Duration of study: Armed Forces Institute of Urology Rawalpindi, Pakistan from Jul 2023 to Aug 2024.

Methodology: One hundred and thirty-five patients aged between 45 to 60 years having acute urinary retention due to benign prostatic enlargement were recruited. were randomly sub-divided in two groups. Patients who received tamsulosin 0.8mg/day were named Group-A (n=70), and those prescribed silodosin 8mg/day were labelled Group-B (n=65). The trial involved no catheter use. Based on every 4 weeks follow up, results were analyzed on international prostate symptoms score (IPSS).

Results: Group-B indicated better catheter free success rate (67%) as compared to Group-A (59%). Successful voiding mean time was recorded as 38 hours in Group-B whereas it was 44 hours in Group-A. Post void mean residual volume was less in silodosin (53 mL) as compared to tamsulosin patients (68 mL). Recurrence of 5.7% was seen in G as compared to roup-B10.7% in Group-A.

Conclusion: Silodosin demonstrated higher success rate in catheter free voiding as compared to Tamsulosin.

Downloads

Download data is not yet available.

References

1. Abdullah O, Yasmin R, Kazmi TH, Ali M, Sadia. Comparison of tamsulosin versus silodosin for treatment of patients with benign prostatic hyperplasia. Pak J Med Health Sci 2023; 16(12): 287. https://doi.org/10.53350/pjmhs20221612287

2. Rethinaswamy FP, Nampoothiri HKN, Mathew B. Comparison of efficacy of tamsulosin, alfuzosin, and silodosin in the management of benign prostatic hyperplasia. Asian J Pharm Clin Res 2023; 16(7): 35-40.

https://doi.org/10.22159/ajpcr.2023.v16i2.46439

3. Pande S, Hazra A, Kundu AK. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial. Indian J Pharmacol 2024; 60(2): 132-136.

https://doi.org/10.4103/0253-7613.144912

4. Rahman FHF, Leonardo K, Ardaya R, Atmoko W, Parikesit D. Efficacy and safety comparison between silodosin and tamsulosin as medical expulsive therapy for distal ureteral stones. Med J Indones 2023; 32(4): 238–245.

https://doi.org/10.13181/mji.oa.247180

5. Lee JH, Kim JH, Oh SJ. Head-to-head comparison of silodosin and tamsulosin in patients with benign prostatic hyperplasia: a systematic review and network meta-analysis. Prostate 2022; 82(3): 239-249.

https://doi.org/10.1002/pros.24267

6. Zhao Y, Li X, Wang L. Comparative efficacy of silodosin and tamsulosin for the treatment of benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. BJU Int 2023; 131(4): 543-551.

https://doi.org/10.1111/bju.15522

7. Kumar S, Goel A, Sankhwar SN, Singh V, Verma A, Pandey M et al. Randomized study comparing silodosin and tamsulosin in the management of benign prostatic hyperplasia in Indian men. J Clin Urol 2020; 13(4): 293-298.

https://doi.org/10.1177/2051415819898261

8. Nitti VW, Brucker BM. Comparative pharmacology of alpha-1 adrenergic receptor blockers for benign prostatic hyperplasia: focus on silodosin. Clin Drug Investig 2020; 40(9): 837-846.

https://doi.org/10.1007/s40261-020-00939-9

9. Chen Y, Xu L, Zhang X. Efficacy of silodosin vs tamsulosin in patients with benign prostatic hyperplasia: a real-world study. Int Urol Nephrol 2023; 55(5): 903-910.

https://doi.org/10.1007/s11255-023-02903-1

10. Lopez-Martinez JM, Hernandez-Gallego B, Serrano-Diaz N. Comparative efficacy of tamsulosin and silodosin in improving urinary symptoms and sexual function in men with benign prostatic hyperplasia: a 12-month randomized controlled trial. Urology 2019; 132(1): 77-84.

https://doi.org/10.1016/j.urology.2019.06.019

11. Seerat U, Mohsin A, Noor S, Muhammad R. A comparative study of Silodosin vs. tamsulosin in the management of benign prostatic hyperplasia: outcomes in a tertiary care setting in Karachi. Int J Endorsing Health Sci Res 2024; 12(4): 222-228.

https://doi.org/10.29052/IJEHSR.v12.i4.2024.222-228

12. Kim TH, Kim SW, Park JY. Efficacy and safety of silodosin versus tamsulosin in patients with benign prostatic hyperplasia: a systematic review and meta-analysis. Urology 2021; 150(1): 35-42. https://doi.org/10.1016/j.urology.2020.08.045

13. Clavell-Hernández J, Hernández-Villegas MT, Plata M. A prospective, randomized, double-blind study comparing silodosin and tamsulosin in patients with acute urinary retention due to benign prostatic hyperplasia. Urology 2020; 141: 55-60.https://doi.org/10.1016/j.urology.2020.03.001

14. Cho KS, Kim JH, Kim SA, Cho JW, Oh YT, Koh JS, et al. A comparative trial of silodosin versus tamsulosin for acute urinary retention secondary to benign prostatic hyperplasia in Korean men. Int Neurourol J 2019; 23(3): 217-223.

https://doi.org/10.5213/inj.1938022.017

15. Matsushita K, Yamaguchi K, Nishiyama H. Comparative efficacy of silodosin and tamsulosin for managing lower urinary tract symptoms in men with benign prostatic hyperplasia: a systematic review and meta-analysis. J Urol 2022; 207(2): 362-371. https://doi.org/10.1097/JU.0000000000000785

16. Ogawa S, Yoshida M, Gotoh M. Comparison of clinical efficacy and safety of silodosin versus tamsulosin in the treatment of benign prostatic hyperplasia: a multicenter, double-blind, placebo-controlled study. Int J Urol 2019; 26(5): 497-503.

https://doi.org/10.1111/iju.13934

17. Guan X, Li W, Chen Y. Efficacy of silodosin versus tamsulosin in improving quality of life in patients with benign prostatic hyperplasia: a multicenter randomized controlled trial. Neurourol Urodyn 2023; 42(3): 345-353.

https://doi.org/10.1002/nau.25015

18. Song Y, Chen H, Wang Y. A head-to-head comparison of silodosin and tamsulosin in the management of lower urinary tract symptoms: a randomized controlled trial. Prostate Cancer Prostatic Dis 2023; 26(1): 77-84.

https://doi.org/10.1038/s41391-022-00451-3

19. Shibata Y, Matsukawa M, Ohtake N, Shirai S, Oka M, Fujii Y et al. Silodosin vs tamsulosin: comparison of efficacy and quality of life in patients with benign prostatic hyperplasia. Andrologia 2020; 52(1): e13491. https://doi.org/10.1111/and.13491

20. Zhou H, Liu Z, Chen L. Efficacy and safety of silodosin versus tamsulosin in patients with benign prostatic hyperplasia: a systematic review and meta-analysis. World J Urol 2022; 40(6): 1363-1372. https://doi.org/10.1007/s00345-021-03992-0

21. Serati M, Aggio G, Braga A, Cattoni E, Torella M, De Nunzio C, et al. Comparing the impact of silodosin and tamsulosin on sexual function in men with benign prostatic hyperplasia: results from a randomized controlled trial. Andrology 2019; 7(1): 84-89.

https://doi.org/10.1111/andr.12574